QLI - BGM Group Ltd.

0   0%

Share volume: 0
Last Updated:
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
N/A
P/E Ratio 
N/A
DAY RANGE
N/A - N/A
EPS 
N/A
52 WEEK RANGE
N/A - N/A
52 WEEK CHANGE
N/A
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Chen Xin
Region: US
Website: qlsyy.net
Employees: 298
IPO year: 2024
Issue type:
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human. In addition, it offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases.

Recent news